Literature DB >> 11507080

Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.

M E Gruys1, T C Back, J Subleski, T A Wiltrout, J K Lee, L Schmidt, M Watanabe, R Stanyon, J M Ward, J M Wigginton, R H Wiltrout.   

Abstract

Interleukin-2-based regimens of biological therapy have shown some clinical promise for the treatment of kidney cancer in humans, although the mechanisms responsible for tumor regression occurring in these patients remain unclear. Preclinical insight into these mechanisms is limited by a paucity of orthotopic animal models of kidney cancer. We have used streptozotocin, an antibiotic and diabetogenic nitrosamine compound derived from Streptomyces achromogenes to induce new kidney tumors in BALB/c mice. Single or multiple doses of streptozotocin induced kidney tumors in up to 25% of mice by 50-90 weeks of age, with up to 18% characterized as renal cell carcinomas (RCCs). Several transplantable lines were obtained from the RCCs, and one of these lines was subsequently cloned. The initial tumor isolates and sublines were histologically reconfirmed to be RCCs, and all grew progressively but slowly (mean survival times, 57 to >100 days) in vivo after intrarenal implant. None of the primary isolates or sublines revealed mutations in either the VHL or Ras genes, although karyotype analysis and chromosome painting revealed the consistent presence of a submetacentric chromosome resulting from the fusion of chromosomes 16 and 19. Biological characterization of these tumors revealed several features analogous to the growth of human kidney cancers, including a propensity for the formation of lung metastases and high vascularity. This hypervascularity is evident by both gross and microscopic analysis and correlates with the expression of several proangiogenic genes. Overall, the features of orthotopic transplantability, slower in vivo growth (relative to the rapid growth rates of other transplantable mouse kidney tumors), propensity for lung metastases, and hypervascularity may make these tumors valuable models for the study of new therapeutic strategies based on antineovascular agents and antitumor cytokines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507080

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Authors:  Qun Jiang; Jonathan M Weiss; Timothy Back; Tim Chan; John R Ortaldo; Sylvie Guichard; Robert H Wiltrout
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

2.  Comparatively analyzing the liver-specific transcriptomic profiles in Kunming mice afflicted with streptozotocin- and natural food-induced type 2 diabetes mellitus.

Authors:  Yanjun Wu; Xiangxing Zhu; Arome Solomon Odiba; Zisheng Lin; Jiancong Wen; Daoyuan Gong; Jing Liang; Shuguang Wu; Ganqiu Lan
Journal:  Mol Biol Rep       Date:  2021-11-30       Impact factor: 2.316

Review 3.  Research-Relevant Conditions and Pathology of Laboratory Mice, Rats, Gerbils, Guinea Pigs, Hamsters, Naked Mole Rats, and Rabbits.

Authors:  Timothy K Cooper; David K Meyerholz; Amanda P Beck; Martha A Delaney; Alessandra Piersigilli; Teresa L Southard; Cory F Brayton
Journal:  ILAR J       Date:  2021-12-31       Impact factor: 1.521

Review 4.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

Review 5.  [Perfusion measurement using the T2* contrast media dynamics in neuro-oncology. Physical basics and clinical applications].

Authors:  M-A Weber; F Risse; F L Giesel; L R Schad; H-U Kauczor; M Essig
Journal:  Radiologe       Date:  2005-07       Impact factor: 0.635

6.  [Noninvasive measurement of relative cerebral blood flow with the blood bolus MRI arterial spin labeling: basic physics and clinical applications].

Authors:  M-A Weber; A Kroll; M Günther; S Delorme; J Debus; F L Giesel; M Essig; H-U Kauczor; L R Schad
Journal:  Radiologe       Date:  2004-02       Impact factor: 0.635

7.  Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells.

Authors:  David J Tate; John R Patterson; Cruz Velasco-Gonzalez; Emily N Carroll; Janie Trinh; Daniel Edwards; Ashok Aiyar; Beatriz Finkel-Jimenez; Arnold H Zea
Journal:  Int J Biol Sci       Date:  2012-09-06       Impact factor: 6.580

8.  Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.

Authors:  Lyse A Norian; Timothy P Kresowik; Henry M Rosevear; Britnie R James; Timothy R Rosean; Andrew J Lightfoot; Tamara A Kucaba; Christopher Schwarz; Christine J Weydert; Michael D Henry; Thomas S Griffith
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

Review 9.  Heading Towards a Possible Rebirth of the Induced Renal Cell Carcinoma Models?

Authors:  Clarisse R Mazzola; Domenico Ribatti
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

10.  Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma.

Authors:  David J Tate; Derek J Vonderhaar; Yupanqui A Caldas; Toye Metoyer; John R Patterson; Diego H Aviles; Arnold H Zea
Journal:  J Hematol Oncol       Date:  2008-09-25       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.